

# Al B Benson Iii

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/232167/publications.pdf>

Version: 2024-02-01

88  
papers

6,197  
citations

117625

34  
h-index

74163

75  
g-index

92  
all docs

92  
docs citations

92  
times ranked

8876  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2392.	7.4	670
2	Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016, 151, 1155-1163.e2.	1.3	498
3	Pancreatic Adenocarcinoma, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1083-1093.	4.9	307
4	NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 693-702.	4.9	289
5	Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. <i>Cancer</i> , 2003, 98, 484-495.	4.1	285
6	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 446-464.	1.6	273
7	The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer. <i>Oncologist</i> , 2007, 12, 38-50.	3.7	218
8	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	27.6	218
9	Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies. <i>Journal of Surgical Oncology</i> , 2019, 120, 85-92.	1.7	201
10	Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293. <i>Medical Oncology</i> , 1996, 13, 87-93.	2.5	183
11	Rectal Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 719-728.	4.9	181
12	Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. <i>Hepatology</i> , 2018, 68, 1429-1440.	7.3	174
13	Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. , 1998, 82, 1250-1259.		171
14	Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. <i>Cancer</i> , 2009, 115, 1849-1858.	4.1	164
15	Cancer patient preferences for quality and length of life. <i>Cancer</i> , 2008, 113, 3459-3466.	4.1	159
16	Neuroendocrine Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 724-764.	4.9	157
17	Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. <i>Oncologist</i> , 2020, 25, e808-e815.	3.7	114
18	Epidemiology, disease Progression, and Economic Burden of Colorectal Cancer. <i>Journal of Managed Care Pharmacy</i> , 2007, 13, 5-18.	2.2	112

#	ARTICLE	IF	CITATIONS
19	The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. <i>Cancer</i> , 2003, 98, 166-175.	4.1	101
20	Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis. <i>Journal of Hepatology</i> , 2012, 56, 1112-1120.	3.7	82
21	Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study. <i>European Journal of Cancer</i> , 2013, 49, 3122-3130.	2.8	82
22	Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1861-1869.	6.4	80
23	<sup>90</sup> Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 665-671.	5.0	79
24	Epidemiology of Anal Canal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 9-15.	1.5	79
25	Fluorouracil Modulation in Colorectal Cancer: Lack of Improvement With N -Phosphonoacetyl- L -Aspartic Acid or Oral Leucovorin or Interferon, But Enhanced Therapeutic Index With Weekly 24-Hour Infusion Schedule—An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 2413-2421.	1.6	76
26	Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group—American College of Radiology Imaging Network Cancer Research Group Trial (E3205). <i>Journal of Clinical Oncology</i> , 2017, 35, 718-726.	1.6	70
27	Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. <i>Journal of Clinical Oncology</i> , 2022, 40, 2163-2171.	1.6	68
28	Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 795-802.	0.5	64
29	Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. , 2020, 8, e000587.		62
30	Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1520-1526.	0.5	57
31	Oltipraz: A laboratory and clinical review. <i>Journal of Cellular Biochemistry</i> , 1993, 53, 278-291.	2.6	56
32	Bevacizumab in the treatment of colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 997-1005.	3.1	52
33	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma. <i>American Journal of Clinical Pathology</i> , 2016, 146, 647-669.	0.7	46
34	New Approaches to the Adjuvant Therapy of Colon Cancer. <i>Oncologist</i> , 2006, 11, 973-980.	3.7	43
35	Chemoradiation of Hepatic Malignancies: Prospective, Phase 1 Study of Full-Dose Capecitabine With Escalating Doses of Yttrium-90 Radioembolization. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1025-1031.	0.8	43
36	Adjuvant Therapy in Stage II Colon Cancer: Current Approaches. <i>Oncologist</i> , 2005, 10, 325-331.	3.7	37

#	ARTICLE	IF	CITATIONS
37	Systemic Therapy for Advanced Appendiceal Adenocarcinoma: An Analysis From the NCCN Oncology Outcomes Database for Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1123-1130.	4.9	37
38	Gemcitabine remains the standard of care for pancreatic cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 135-137.	27.6	33
39	Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies. <i>Clinical Colorectal Cancer</i> , 2016, 15, 37-46.	2.3	32
40	Comparison of Cancer Burden and Nonprofit Organization Funding Reveals Disparities in Funding Across Cancer Types. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 849-854.	4.9	32
41	New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancers: Cooperative Group Strategies for Assessing Optimal Approaches in Early-Stage Disease. <i>Clinical Cancer Research</i> , 2007, 13, 6913s-6920s.	7.0	31
42	Adjuvant Chemotherapy of Stage III Colon Cancer. <i>Seminars in Oncology</i> , 2005, 32, 74-77.	2.2	27
43	TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. <i>JMIR Research Protocols</i> , 2019, 8, e11545.	1.0	27
44	Care for a Patient With Cancer As a Project: Management of Complex Task Interdependence in Cancer Care Delivery. <i>Journal of Oncology Practice</i> , 2016, 12, 1101-1113.	2.5	25
45	Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers. <i>Cancer</i> , 2012, 118, 5997-6004.	4.1	24
46	Preoperative prediction of perineural invasion and KRAS mutation in colon cancer using machine learning. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3165-3174.	2.5	23
47	Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). <i>Journal of Clinical Oncology</i> , 2022, 40, 740-751.	1.6	20
48	From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. <i>Value in Health</i> , 2018, 21, 1062-1068.	0.3	19
49	TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World. <i>Oncologist</i> , 2019, 24, 1446-1452.	3.7	19
50	Biomarker Testing for Breast, Lung, and Gastroesophageal Cancers at NCI Designated Cancer Centers. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	18
51	Young Age and Aggressive Treatment in Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 613.	7.4	18
52	Preoperative assessment of lymph node metastasis in Colon Cancer patients using machine learning: a pilot study. <i>Cancer Imaging</i> , 2020, 20, 30.	2.8	18
53	Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1528-1534.	4.9	17
54	Preventing venous thromboembolism in oncology practice: Use of risk assessment and anticoagulation prophylaxis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1211-1215.	2.3	17

#	ARTICLE	IF	CITATIONS
55	Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 738-746.	0.8	16
56	Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. <i>Oncologist</i> , 2019, 24, 1039-e642.	3.7	16
57	Preoperative chemotherapy for locally advanced resectable colon cancer - a new treatment paradigm in colon cancer?. <i>Annals of Translational Medicine</i> , 2013, 1, 11.	1.7	15
58	Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1279-1287.	0.5	14
59	Pembrolizumab for the treatment of gastric cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1177-1187.	2.4	13
60	MRI radiomics for early prediction of response to vaccine therapy in a transgenic mouse model of pancreatic ductal adenocarcinoma. <i>Journal of Translational Medicine</i> , 2020, 18, 61.	4.4	13
61	Anal Cancer: Emerging Standards in a Rare Disease. <i>Journal of Clinical Oncology</i> , 2022, 40, 2774-2788.	1.6	13
62	Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors. <i>American Health and Drug Benefits</i> , 2017, 10, 408-415.	0.5	12
63	Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 232-245.	3.8	10
64	Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. <i>Oncologist</i> , 2019, 24, 1066-1075.	3.7	10
65	Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. <i>Oncologist</i> , 2019, 24, 1056-1065.	3.7	8
66	Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis. <i>World Journal of Gastroenterology</i> , 2017, 23, 6128-6136.	3.3	8
67	Detection of Immunotherapeutic Response in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI Radiomics: A Preliminary Investigation. <i>Academic Radiology</i> , 2020, 28, e147-e154.	2.5	8
68	Recent and ongoing clinical trials for treating colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 871-880.	4.1	7
69	Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. <i>Gastric Cancer</i> , 2021, 24, 1330-1340.	5.3	7
70	Management of colorectal cancer during the COVID-19 pandemic: Recommendations from a statewide multidisciplinary cancer collaborative. <i>Journal of Surgical Oncology</i> , 2022, 125, 560-563.	1.7	6
71	Real-World Treatment Patterns for Lung Neuroendocrine Tumors: A Claims Database Analysis. <i>Oncology</i> , 2018, 94, 281-288.	1.9	5
72	Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. <i>Oncologist</i> , 2021, 26, 651-659.	3.7	5

#	ARTICLE	IF	CITATIONS
73	Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. <i>Neuroendocrinology</i> , 2021, 111, 850-862.	2.5	4
74	Role of NCCN in Integrating Cancer Clinical Practice Guidelines into the Healthcare Debate. <i>American Health and Drug Benefits</i> , 2008, 1, 28-33.	0.5	4
75	S-1: another oral agent for patients with colorectal cancer. <i>Lancet Oncology</i> , The, 2013, 14, 1244-1245.	10.7	3
76	HSR19-094: A Comparison of Cancer Burden and Funding From the National Cancer Institute and Nonprofit Organizations Reveals Disparities in the Distribution of Funding Across Cancer Types. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, HSR19-094.	4.9	3
77	Have the changes in treatment of rectal cancer made a significant difference to our patients?. <i>Oncology</i> , 2011, 25, 1323-9.	0.5	3
78	Adjuvant chemotherapy after neoadjuvant chemoradiation and surgery: A quest to improve survival for stage II and III rectal cancer. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 151-157.	0.5	2
79	Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency. <i>Pancreas</i> , 2020, 49, 408-412.	1.1	2
80	Risk assessment and adjuvant systemic therapy in resected stage II colon cancer. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 158-165.	0.5	0
81	What Level of Evidence: The Elusive Balance in Drug Development. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 955-958.	4.9	0
82	Prognostic and Predictive Markers in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2011, 7, 267.	0.5	0
83	Advances in Treatment Selection for Patients with Metastatic Colorectal Cancer. <i>Advances in Oncology</i> , 2021, 1, 297-310.	0.2	0
84	Clinical trials as a path toward equity. <i>Cancer</i> , 2021, 127, 3717-3719.	4.1	0
85	ISGIO's Role in the Global Advancement of GI Oncology: Will We be Ready for the Future?. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, 1.	0.7	0
86	Future directions in adjuvant therapy for rectal cancer. <i>Oncology</i> , 2002, 16, 45-51.	0.5	0
87	Bevacizumab in combination with 5-fluorouracil-based chemotherapy in the second-line treatment of metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 747.	0.3	0
88	Applications of oral fluoropyrimidines in colon cancer: their role and new directions. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2003, 1 Suppl 3, S-17-21.	4.9	0